Nicola Gebbia

University of Palermo — Italy

Medicine · Health Sciences

30h-index5.0kcitations95works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(13), Cancer-related Molecular Pathways(10), Lung Cancer Treatments and Mutations(9), Genetic factors in colorectal cancer(9), Cancer Treatment and Pharmacology(9)

Publications92 total

Data from Targeting Human γδ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
2023Open Access
Supplementary Figures 1-4, Tables 1-2 from Targeting Human γδ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
2023Open Access
Supplementary Figures 1-4, Tables 1-2 from Targeting Human γδ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
2023Open Access
Data from Targeting Human γδ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
2023Open Access
Biweekly Combination of Trastuzumab, Docetaxel and Gemcitabine for HER2-Positive Metastatic Breast Cancer: Results of a Phase II GOIM Study
Future Oncology·2014· 3 cited
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
Cancer Treatment Reviews·2010· 143 cited
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Cancer Treatment Reviews·2010· 106 citedOpen Access
PML down‐regulation in soft tissue sarcomas
Journal of Cellular Physiology·2010· 5 cited
miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells
Journal of Cellular Physiology·2010· 218 citedOpen Access
Anti-endothelin drugs in solid tumors
Expert Opinion on Emerging Drugs·2010· 19 citedOpen Access
Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis.
Blood·2009
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry·2009· 13 cited
Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules
Hematology Reports·2009· 7 citedOpen Access
Gemcitabine‐based doublets versus single‐agent therapy for elderly patients with advanced nonsmall cell lung cancer
Cancer·2009· 24 citedOpen Access
Author Index Vol. 77, Suppl. 1, 2009
Oncology·2009Open Access
Abstracts
Oncology·2009
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
Oncology·2009· 48 citedOpen Access
Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a γδ-T Lymphocytes-Mediated Activation Mechanism
Journal of Medicinal Chemistry·2008· 71 citedOpen Access
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells
Cancer Letters·2008· 74 cited
Antiproliferative Agents That Interfere with the Cell Cycle at the G<sub>1</sub>→S Transition: Further Development and Characterization of a Small Library of Stilbene‐Derived Compounds
ChemMedChem·2007· 9 cited
page 1 of 5Next →

Frequent Co-authors

Antonio Russo(20), Viviana Bazan(18), Gaetano Leto(11), Maria Rosaria Valerio(9), Manlio Tolomeo(9), Francesca Maria Tumminello(9), Gabriella Dardanoni(9), Manuela Migliavacca(8), Fabio Fulfaro(8), Daniele Simoni(8), Rosa Maria Tomasino(8), Marcella Macaluso(7), S Corsale(7), Stefania Grimaudo(6), Lucia Crosta(6), Francesco Paolo Invidiata(6), Giuseppe Pizzolanti(6), Giuseppe Colucci(5), Vittorio Gebbia(5), Francesco Dieli(5)